Atara Biotherapeutics (NASDAQ:ATRA) CEO Anhco Nguyen Sells 5,241 Shares of Stock

Posted by Brenda Bartman on May 21st, 2026

Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) CEO Anhco Nguyen sold 5,241 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $9.13, for a total value of $47,850.33. Following the transaction, the chief executive officer owned 137,837 shares of the company’s stock, valued at approximately $1,258,451.81. This represents a 3.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Atara Biotherapeutics Trading Up 0.4%

Shares of NASDAQ ATRA opened at $9.45 on Thursday. The stock has a 50 day simple moving average of $5.98 and a 200-day simple moving average of $8.97. The company has a market cap of $85.14 million, a PE ratio of -14.10 and a beta of -0.30. Atara Biotherapeutics, Inc. has a 12-month low of $3.92 and a 12-month high of $19.15.

Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.04. The business had revenue of $0.52 million during the quarter, compared to the consensus estimate of $2.90 million. Atara Biotherapeutics had a negative return on equity of 79.12% and a negative net margin of 40.91%. Sell-side analysts forecast that Atara Biotherapeutics, Inc. will post 0.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ATRA shares. Canaccord Genuity Group set a $13.00 price objective on Atara Biotherapeutics and gave the stock a “buy” rating in a research report on Friday, May 8th. Weiss Ratings reissued a “sell (d)” rating on shares of Atara Biotherapeutics in a report on Friday, March 27th. Wall Street Zen raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Freedom Capital raised Atara Biotherapeutics from a “strong sell” rating to a “hold” rating in a report on Monday. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Atara Biotherapeutics presently has an average rating of “Hold” and an average target price of $9.50.

View Our Latest Research Report on Atara Biotherapeutics

Institutional Investors Weigh In On Atara Biotherapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC boosted its position in shares of Atara Biotherapeutics by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 60,136 shares of the biotechnology company’s stock valued at $464,000 after purchasing an additional 1,457 shares in the last quarter. Marshall Wace LLP acquired a new stake in Atara Biotherapeutics during the second quarter valued at approximately $327,000. Raymond James Financial Inc. acquired a new stake in Atara Biotherapeutics during the second quarter valued at approximately $31,000. Vanguard Group Inc. boosted its holdings in Atara Biotherapeutics by 6.6% during the third quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company’s stock worth $2,915,000 after buying an additional 12,677 shares in the last quarter. Finally, GSA Capital Partners LLP boosted its holdings in Atara Biotherapeutics by 33.8% during the third quarter. GSA Capital Partners LLP now owns 26,213 shares of the biotechnology company’s stock worth $376,000 after buying an additional 6,622 shares in the last quarter. 70.90% of the stock is owned by institutional investors and hedge funds.

About Atara Biotherapeutics

(Get Free Report)

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.